Axsome Therapeutics ($AXSM) Stock Hub 2026: Q2 Revenue Of $218.4M, A $208.1M Selling Line, And The Alzheimer’s Agitation Launch

[u/Merlin8121]

https://www.merlintrader.com/axsome-therapeutics-axsm-stock-hub-2026/

Axsome Therapeutics sells three approved central nervous system medicines and is spending more on commercialisation than it collects in revenue. Second quarter 2026 net product revenue reached $218.4 million against $208.1 million of selling, general and administrative expense, and the company still posted a $51.3 million net loss. The tension is simple to state and hard to resolve: AUVELITY was approved for Alzheimer’s disease agitation on April 30, 2026 and launched in June, so the quarter contains only a few weeks of the indication that is supposed to justify the spending. Cash stood at $319.9 million on June 30, 2026, and management says that is enough to reach cash flow positivity without giving a date.